Evidence map›Paper›PMID 38838453›Full record

ArticleParkinsonism & related disorders2024

Replication and reliability of Parkinson's disease clinical subtypes.

Therese V Cash, Christina N Lessov-Schlaggar, Erin R Foster, Peter S Myers, Joshua J Jackson, Baijayanta Maiti, Paul T Kotzbauer, Joel S Perlmutter, Meghan C Campbell

Abstract read
In one paragraph

Article in Parkinsonism & related disorders, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Therese V CashDepartment of Neurology, Washington University School of Medicine, USA.
Christina N Lessov-SchlaggarDepartment of Psychiatry, Washington University School of Medicine, USA.
Erin R FosterDepartment of Neurology, Washington University School of Medicine, USA; Department of Psychiatry, Washington University School of Medicine, USA; Program in Occupational Therapy, Washington University School of Medicine, USA.
Peter S MyersDepartment of Neurology, Washington University School of Medicine, USA.
Joshua J JacksonDepartment of Psychological and Brain Sciences, Washington University in St. Louis, USA.
Baijayanta MaitiDepartment of Neurology, Washington University School of Medicine, USA; Department of Radiology, Washington University School of Medicine, USA.
Paul T KotzbauerDepartment of Neurology, Washington University School of Medicine, USA.
Joel S PerlmutterDepartment of Neurology, Washington University School of Medicine, USA; Department of Radiology, Washington University School of Medicine, USA; Department of Neuroscience, Washington University School of Medicine, USA; Program in Occupational Therapy, Washington University School of Medicine, USA; Program in Physical Therapy, Washington University School of Medicine, USA.
Meghan C CampbellDepartment of Neurology, Washington University School of Medicine, USA; Department of Radiology, Washington University School of Medicine, USA. Electronic address: meghanc@wustl.edu.

Funding

Medicinal Chemistry CoreU19NS110456 · NINDS · UNIVERSITY OF PENNSYLVANIA · PI ROBERT H MACH · 2019 to 2026
$44.1M
Project: Predicting PhenoconversionU19AG071754 · NIA · WASHINGTON UNIVERSITY · PI Bradley F Boeve, Yo-El S Ju · 2021 to 2026
$41.2M
Washington University Institute of Clinical and Translational Sciences (KL2) KL2TR002346 · NCATS · WASHINGTON UNIVERSITY · PI Dominic N Reeds · 2017 to 2026
$14.0M
INVESTIGATIONS OF DEMENTIA IN PARKINSON DISEASER01NS075321 · NINDS · WASHINGTON UNIVERSITY · PI CAMPBELL, MEGHAN C, PERLMUTTER, JOEL SYNES · 2011 to 2021
$8.2M
Dystonia Coalition- Pilot ProjectU54NS116025 · NINDS · EMORY UNIVERSITY · PI JINNAH, HYDER A · 2019 to 2023
$7.1M
Dystonia CoalitionU54NS065701 · NINDS · EMORY UNIVERSITY · PI JINNAH, HYDER A · 2009 to 2014
$7.0M
Neurocognitive Impact of Hypoglycemia in type 1 DiabetesR01DK064832 · NIDDK · WASHINGTON UNIVERSITY · PI HERSHEY, TAMARA G · 2003 to 2020
$6.0M
Protein Aggregation and Neurotransmitter Deficits in Parkinson DiseaseR01NS097799 · NINDS · WASHINGTON UNIVERSITY · PI PAUL T KOTZBAUER · 2016 to 2026
$5.8M
PET PROBES FOR IMAGING THE VESICULAR ACETYLCHOLINE TRANSPORTERR01NS075527 · NINDS · WASHINGTON UNIVERSITY · PI TU, ZHUDE · 2011 to 2021
$4.9M
Structural Biology of Alpha-Synuclein in Lewy Body DementiaRF1NS110436 · NINDS · WASHINGTON UNIVERSITY · PI KOTZBAUER, PAUL T, RIENSTRA, CHAD M · 2023 to 2023
$4.2M
Parkinson Disease Clinical Subtypes: Validation, Clinical Utility, and Biological CorrelatesR01NS097437 · NINDS · WASHINGTON UNIVERSITY · PI MEGHAN C CAMPBELL · 2017 to 2026
$4.1M
STRUCTURAL BIOLOGY OF ALPHA-SYNUCLEIN IN LEWY BODY DEMENTIAU01NS110436 · NINDS · WASHINGTON UNIVERSITY · PI KOTZBAUER, PAUL T · 2018 to 2022
$4.1M
NCATS NIH HHS KL2 TR002346NCATS NIH HHS U54 TR001456NCCIH NIH HHS R33 AT010753NCCIH NIH HHS R34 AT011015NCCIH NIH HHS R61 AT010753NIA NIH HHS R01 AG050263NIA NIH HHS R01 AG061162NIA NIH HHS R01 AG065214NIA NIH HHS R21 AG063974NIA NIH HHS RF1 AG064937NIA NIH HHS U19 AG071754NIDCD NIH HHS K01 DC017522NIDDK NIH HHS R01 DK064832NIDDK NIH HHS R01 DK126826NIEHS NIH HHS R01 ES029524NINDS NIH HHS K23 NS125107NINDS NIH HHS R01 NS075321NINDS NIH HHS R01 NS075527NINDS NIH HHS R01 NS092865NINDS NIH HHS R01 NS097437NINDS NIH HHS R01 NS097799NINDS NIH HHS R01 NS103957NINDS NIH HHS R01 NS107281NINDS NIH HHS R01 NS109487NINDS NIH HHS R01 NS118146NINDS NIH HHS R01 NS124738NINDS NIH HHS R21 NS123860NINDS NIH HHS RF1 NS075321NINDS NIH HHS RF1 NS110436NINDS NIH HHS U01 NS110436NINDS NIH HHS U10 NS077384NINDS NIH HHS U19 NS110456NINDS NIH HHS U54 NS065701NINDS NIH HHS U54 NS116025
6 · The paper itself

Abstract

backgroundWe recently identified three distinct Parkinson's disease subtypes: "motor only" (predominant motor deficits with intact cognition and psychiatric function); "psychiatric & motor" (prominent psychiatric symptoms and moderate motor deficits); "cognitive & motor" (cognitive and motor deficits).

objectiveWe used an independent cohort to replicate and assess reliability of these Parkinson's disease subtypes.

methodsWe tested our original subtype classification with an independent cohort (N = 100) of Parkinson's disease participants without dementia and the same comprehensive evaluations assessing motor, cognitive, and psychiatric function. Next, we combined the original (N = 162) and replication (N = 100) datasets to test the classification model with the full combined dataset (N = 262). We also generated 10 random split-half samples of the combined dataset to establish the reliability of the subtype classifications. Latent class analyses were applied to the replication, combined, and split-half samples to determine subtype classification.

resultsFirst, LCA supported the three-class solution - Motor Only, Psychiatric & Motor, and Cognitive & Motor- in the replication sample. Next, using the larger, combined sample, LCA again supported the three subtype groups, with the emergence of a potential fourth group defined by more severe motor deficits. Finally, split-half analyses showed that the three-class model also had the best fit in 13/20 (65%) split-half samples; two-class and four-class solutions provided the best model fit in five (25%) and two (10%) split-half replications, respectively.

conclusionsThese results support the reproducibility and reliability of the Parkinson's disease behavioral subtypes of motor only, psychiatric & motor, and cognitive & motor groups.

Indexed as

Parkinson DiseaseAgedCognitive DysfunctionCohort StudiesFemaleHumansMaleMental DisordersMiddle AgedReproducibility of ResultsClassificationLatent class analysisParkinson diseasePsychometrics

Identifiers

PMID38838453
PMCPMC11590651

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.